Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Chiumente

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Therapeutic Advances in Medical Oncology|June 18, 2020
Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the medianAndrea Messori, Marco Chiumente, Daniele Mengato
European Journal of Hospital Pharmacy : Science and Practice|December 1, 2020
Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become availableAndrea Messori, Laura Bartoli, Daniele Mengato, et al.
Cureus|February 2, 2023
Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal AntibodyAndrea Messori, Melania Rivano, Daniele Mengato, et al.
Hematology Reports|December 22, 2023
Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect ComparisonsMelania Rivano, Daniele Mengato, Marco Chiumente, et al.
Frontiers in Pharmacology|February 9, 2017
The Life Cycle of Health Technologies. Challenges and Ways ForwardIñaki Gutiérrez-Ibarluzea, Marco Chiumente, Hans-Peter Dauben
Chinese Clinical Oncology|October 11, 2023
Tislelizumab plus chemotherapy vs. pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trialsAndrea Messori, Melania Rivano, Marco Chiumente, et al.
Cureus|March 3, 2022
Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny MethodSabrina Trippoli, Lorenzo Di Spazio, Marco Chiumente, et al.
International Journal of Technology Assessment in Health Care|December 7, 2020
Toward a common understanding of competencies for health technology assessment: enhancing educational and training programs around the globeDebjani Mueller, Iñaki Gutierrez-Ibarluzea, Marco Chiumente, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 8, 2020
The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 InhibitorsAndrea Messori, Laura Bartoli, Marco Chiumente, et al.
Cancers|April 13, 2023
Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination RegimensAndrea Ossato, Daniele Mengato, Marco Chiumente, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Therapeutic Advances in Medical Oncology|June 18, 2020
Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the medianAndrea Messori, Marco Chiumente, Daniele Mengato
European Journal of Hospital Pharmacy : Science and Practice|December 1, 2020
Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become availableAndrea Messori, Laura Bartoli, Daniele Mengato, et al.
Cureus|February 2, 2023
Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal AntibodyAndrea Messori, Melania Rivano, Daniele Mengato, et al.
Hematology Reports|December 22, 2023
Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect ComparisonsMelania Rivano, Daniele Mengato, Marco Chiumente, et al.
Frontiers in Pharmacology|February 9, 2017
The Life Cycle of Health Technologies. Challenges and Ways ForwardIñaki Gutiérrez-Ibarluzea, Marco Chiumente, Hans-Peter Dauben
Chinese Clinical Oncology|October 11, 2023
Tislelizumab plus chemotherapy vs. pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trialsAndrea Messori, Melania Rivano, Marco Chiumente, et al.
Cureus|March 3, 2022
Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny MethodSabrina Trippoli, Lorenzo Di Spazio, Marco Chiumente, et al.
International Journal of Technology Assessment in Health Care|December 7, 2020
Toward a common understanding of competencies for health technology assessment: enhancing educational and training programs around the globeDebjani Mueller, Iñaki Gutierrez-Ibarluzea, Marco Chiumente, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 8, 2020
The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 InhibitorsAndrea Messori, Laura Bartoli, Marco Chiumente, et al.
Cancers|April 13, 2023
Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination RegimensAndrea Ossato, Daniele Mengato, Marco Chiumente, et al.
Pageof 6